Biogen

The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.

Samsung Bioepis and Biogen's OPUVIZ™, a biosimilar referencing Eylea (aflibercept), recommended for marketing authorization by the European Medicines Agency for treating neovascular AMD, macular oedema secondary to RVO, DME, and myopic CNV.

Samsung Bioepis and Biogen announce EMA's positive opinion for SB15 40mg/mL (OPUVIZ) marketing authorisation, recommended for treating neovascular age-related macular degeneration, macular oedema, diabetic macular oedema, and myopic choroidal neovascularisation. The European Commission will now decide on approval.

A novel drug molecule developed by Biogen could lead to new treatments for Parkinson's disease in younger patients by reactivating the parkin protein, which clears damaged mitochondria, according to research published in *Nature Communications*.

Two new Alzheimer's drugs, lecanemab and donanemab, spark controversy over their effectiveness and cost, with some experts seeing them as a breakthrough and others as a disappointment. The drugs reduce cognitive decline by about 30% but come with risks and high costs, leading to differing national approvals. Critics argue the benefits are minimal, while supporters believe they offer crucial extra months of autonomy.

The global Biotechnology Market is projected to reach USD 6.24 trillion by 2032, driven by R&D investments, healthcare demand, and advancements in pharmaceuticals, agriculture, and environmental management.

Article sent to my@email.address. All fields required; separate multiple recipients with a semicolon. Active subscribers access full article; others directed to abstract.

Biogen has led MS research for 25+ years, advancing from MRI to DMTs. Future focus includes refining diagnosis with biomarkers and targeting CNS for treatment, aiming for personalized MS care and potential disease reversal.

USC's AI for AD project, led by Paul Thompson and Jose-Luis Ambite, uses federated learning to analyze MRI scans and blood tests for early Alzheimer’s detection, aiming to personalize treatments and discover new drugs.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. The analysis reveals AbbVie's high Price to Earnings (64.53), Price to Book (50.28), and Price to Sales (6.22) ratios, suggesting a potentially overvalued stock. However, its high Return on Equity (18.4%), EBITDA ($5.0B), and gross profit ($10.26B) indicate strong profitability and operational efficiency. The company's low revenue growth (4.31%) compared to the industry average (28.79%) raises concerns about future performance.